Welcome to our dedicated page for MetaVia SEC filings (Ticker: MTVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MetaVia Inc. (MTVA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer focused on cardiometabolic diseases. MetaVia files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-37809 as a Delaware corporation with principal offices in Cambridge, Massachusetts. These filings offer detailed information on clinical progress, financial results, capital market actions, and interactions with The Nasdaq Capital Market.
Among MetaVia’s recent filings are several Current Reports on Form 8-K that describe material events. One 8-K discusses a notice from Nasdaq regarding non-compliance with the minimum bid price requirement and a subsequent 180-day extension to May 26, 2026 to regain compliance, as well as the company’s intention to consider options such as a reverse stock split. Another 8-K references the company’s press release announcing a 1-for-11 reverse stock split of its common stock, which was implemented to help meet Nasdaq’s continued listing standards. A later press release, also furnished via 8-K, reports that MetaVia regained compliance with Nasdaq’s minimum bid price requirement and that the listing matter was closed.
Other 8-K filings furnish clinical and corporate updates, including positive Phase 2a data for vanoglipel (DA-1241) in presumed MASH patients and references to improvements in HbA1c, liver inflammation, fibrosis markers, and lipidomic profiles. MetaVia also uses Form 8-K to furnish its quarterly financial results and to provide access to updated corporate presentations, which summarize the status of its DA-1726 and vanoglipel programs and outline its cardiometabolic disease strategy.
Through Stock Titan, users can review these MetaVia SEC filings in one place and use AI-powered tools to summarize key points from complex disclosures. Filings such as 10-K annual reports, 10-Q quarterly reports, and additional 8-K current reports, when available, can help investors and analysts understand MetaVia’s R&D spending, clinical development milestones, capital structure changes, and Nasdaq listing compliance history. Insider transaction reports on Form 4, if filed, can also be accessed to see reported purchases or sales by MetaVia’s officers, directors, or significant shareholders.
MetaVia Inc. reported a key operational milestone in its obesity program. All enrolled active patients in Part 3 of its Phase 1 trial of DA-1726 have completed dose titration and are now receiving their highest target doses of 48 mg and 64 mg in the two cohorts.
Part 3 includes two 16-week titration regimens designed to test one-step and two-step dose escalation, with about 40 obese but otherwise healthy adults randomized 4:1 to active drug versus placebo. The company reiterated that topline data from this Phase 1 Part 3 study remain on track for release in the fourth quarter of 2026.
MetaVia highlighted earlier Phase 1 multiple ascending dose results where DA-1726 produced 9.1% mean weight loss at the 48 mg dose over 8 weeks, along with improvements in waist circumference, glycemic control, and early liver signals, supporting the potential of its dual GLP-1/glucagon mechanism in obesity and related metabolic disease.
MetaVia Inc. filed a Form 8-K to report a prospectus supplement tied to its existing at-the-market equity program. The company may sell up to $4,000,000 of common stock through or to Ladenburg Thalmann & Co. Inc. under a previously signed At The Market Offering Agreement.
Honigman LLP issued a legal opinion on the validity of the shares that may be issued under this arrangement, which is included as Exhibit 5.1. The filing clarifies that it is not itself an offer to sell securities and that any sales must comply with applicable state and federal securities laws.
Metavia Inc. registers the offer and sale of up to an aggregate offering price of $4,000,000 of its common stock under an At-The-Market sales agreement with Ladenburg Thalmann & Co. Inc.
The supplement increases the prior ATM capacity from $2,300,000. Through the date of the supplement the company sold $2,126,303 of common stock under the Sales Agreement. The filing cites a last reported sales price of $1.45 per share on July 1, 2026 and an aggregate market value of shares held by non-affiliates of $18,438,694 based on 4,789,271 shares at $3.85 per share on May 22, 2026.
Tursi James Patrick reported acquisition or exercise transactions in this Form 4 filing.
MetaVia Inc. director James Patrick Tursi received a grant of 17,186 shares of Common Stock as restricted stock units under the company’s Amended and Restated 2022 Equity Incentive Plan. These units vest on the earlier of June 8, 2027 or the day immediately prior to MetaVia’s 2027 annual stockholders meeting, contingent on his continued service. Following this award, Tursi beneficially owns 20,568 shares. The filing notes that this total reflects MetaVia’s 1-for-11 reverse stock split completed on December 4, 2025.
STRICKLAND D GORDON reported acquisition or exercise transactions in this Form 4 filing.
MetaVia Inc. director STRICKLAND D GORDON received a grant of 17,186 restricted stock units of Common Stock under the company’s Amended and Restated 2022 Equity Incentive Plan. These units vest on the earlier of June 8, 2027 or the day before the 2027 annual stockholders meeting, if he continues in service.
Following the award, he beneficially owns 21,339 shares, an amount that reflects MetaVia’s 1-for-11 reverse stock split completed on December 4, 2025. The filing shows a compensation-related equity grant rather than an open‑market trade.
Salsbury Michael reported acquisition or exercise transactions in this Form 4 filing.
MetaVia Inc. director Michael Salsbury received a grant of 17,186 restricted stock units under the company’s Amended and Restated 2022 Equity Incentive Plan. These RSUs vest on the earlier of June 8, 2027 or the day immediately prior to MetaVia’s 2027 annual stockholder meeting, contingent on his continued service.
Under the company’s non-employee director compensation policy, Salsbury elected to defer settlement of the RSUs into common shares until the earlier of just before a Change in Control, or within 60 days after his retirement, other separation from service, or death. Following this award, he beneficially owns 21,338 shares. The filing also notes prior adjustment of his holdings for a 1-for-11 reverse stock split completed on December 4, 2025.
GROVES JASON L reported acquisition or exercise transactions in this Form 4 filing.
MetaVia Inc. director Jason L. Groves received an award of 17,186 restricted stock units (RSUs) of Common Stock as equity compensation. The RSUs were granted at no cash cost and increase his direct beneficial ownership to 21,338 shares.
The RSUs vest on the earlier of June 8, 2027 or the day immediately prior to MetaVia’s 2027 annual meeting of stockholders, contingent on his continued service. Under the company’s non-employee director compensation policy, Groves elected to defer settlement of the shares until immediately before a change in control or within 60 days after his retirement, separation from service, or death. Reported holdings also reflect MetaVia’s 1-for-11 reverse stock split completed on December 4, 2025.
KOVEN ANDREW I reported acquisition or exercise transactions in this Form 4 filing.
MetaVia Inc. director Andrew I. Koven received an equity grant of 17,186 restricted stock units (RSUs) of common stock. The RSUs were granted under MetaVia's Amended and Restated 2022 Equity Incentive Plan at no cash cost to him.
The award vests on the earlier of June 8, 2027 or the day immediately prior to MetaVia's 2027 annual stockholder meeting, as long as he continues serving through that date. Koven elected to defer receipt of the underlying shares until immediately before a change in control, or within 60 days after his retirement, other separation from service, or death. Following this grant, he beneficially owns 21,339 shares, adjusted for a 1-for-11 reverse stock split completed on December 4, 2025.
Glickman Mark A reported acquisition or exercise transactions in this Form 4 filing.
MetaVia Inc. director Mark A. Glickman received a grant of 17,186 shares of Common Stock in the form of restricted stock units under the company’s Amended and Restated 2022 Equity Incentive Plan. These units vest on the earlier of June 8, 2027 or the day immediately prior to MetaVia’s 2027 annual stockholders’ meeting, subject to his continued service. Following this award, he beneficially owns 20,629 shares, reflecting adjustments from MetaVia’s 1-for-11 reverse stock split completed on December 4, 2025.
MetaVia Inc. reported results from its virtual 2026 annual stockholder meeting. Stockholders approved a first amendment to the 2022 Equity Incentive Plan, increasing the shares available for grants by 200,000 shares of common stock while leaving all other plan terms unchanged.
All five proposals on the ballot passed. Two Class I directors were elected to terms ending at the 2029 annual meeting, stockholders ratified BDO USA, P.C. as independent auditor for the 2026 fiscal year, approved a Reverse Stock Split Proposal, the equity plan amendment, and an adjournment proposal. A total of 2,866,545 shares were present and entitled to vote, constituting a quorum.